Flutamide is an antiandrogen used for locally confined stage B2-C and D-2 metastatic prostate carcinoma. An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Mechanism
- Curator reviewed
Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.
- Primary indication
- For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostateCurator reviewed · 2 structured indications
- Formula / weight
- C11H11F3N2O3 · 276.2118 g/mol (avg)
- First approval
- Canada, 1996 · United States, 1989
- Also known as
- NFBA · Niftolid · Niftolide
- Code names
- SCH-13521
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
MKXKFYHWDHIYRV-UHFFFAOYSA-NSMILESCC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)FTargets
Transporters
What you can answer from here — as of September 23, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Flutamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account